Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Procyclidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 8/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.97 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.97 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cycrimine SCHEMBL1235292 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL30061697 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL5502902 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL42410 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL1320615 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Procyclidine SCHEMBL147344 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34646 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Cycrimine SCHEMBL249004 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34645 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| (S)-Procyclidine SCHEMBL519431 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-218474895-U | 3-methylpyridine rectifying device | 安徽瑞邦生物科技有限公司 | 2023-02-14 | — | — | CN | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022069952-A1 | PROCESS FOR PREPARING ORODISPERSIBLE FILM SUITABLE FOR DIVERSE ACTIVE INGREDIENTS | LULLA GEETA (IN) | 2022-04-07 | — | — | WO | claimed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| CN-107573994-A | A kind of metal-cutting oil with rust-proof effect | 吴江华威特种油有限公司 | 2018-01-12 | — | — | CN | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0527835-B1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORP (US) | 1994-10-26 | — | — | EP | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| US-4945097-A | THERAPY FOR ANOXIA, HYPOXIA, OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-07-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CHRM1 1068/4885CHRM2 2141/4885CHRM3 979/4885 |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | CHRM1 8/4885CHRM2 5/4885CHRM3 1/4885 |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | CHRM1 4876/4885CHRM2 4822/4885CHRM3 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.